drugset / Trial / NCT04697576

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

NCT04697576

Phase 1 Recruiting 36 enrolled Carlo Contreras
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase I trial investigates the effects of influenza vaccine in treating patients with stage I-IV melanoma. While intramuscular administration of influenza vaccine provides immunization against the influenza virus, giving influenza vaccine directly into the tumor (intralesional) may decrease the size of the injected melanoma tumor, or the extent of the melanoma within the body.

Timeline

Start
2021-10-20
Primary completion
2027-09-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine Intramuscular
Background Ipilimumab Monoclonal antibody
Background Nivolumab Monoclonal antibody
Background Pembrolizumab Monoclonal antibody
Background Relatlimab Monoclonal antibody